HAEHaemonetics Corp.
HAE
Haemonetics Corp.638
Mkt Cap
$2.66BVolume
2.0052W High
$87.3252W Low
$47.32PE Ratio
16.29HAE Fundamentals
Price
$59.27Prev Close
$57.32Open
$57.2850D MA
$60.27Beta
0.62Avg. Volume
801,475.61EPS (Annual)
$3.31P/B
3.05Rev/Employee
$450,156.80$4,182.21
Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages
Haemonetics Corporation (NYSE:HAE - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the stock, MarketBeat reports...
MarketBeat·4d ago
Harbor Capital Advisors Inc. Sells 22,228 Shares of Haemonetics Corporation $HAE
Harbor Capital Advisors Inc. lowered its position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) by 51.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,631 shares of the medical instruments supplier's stock after selling...
MarketBeat·9d ago
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026 Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026 PR Newswire...
PR Newswire·13d ago
Allspring Global Investments Holdings LLC Sells 121,063 Shares of Haemonetics Corporation $HAE
Allspring Global Investments Holdings LLC lessened its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 11.4% in the fourth quarter, according to the company in its most recent 13F filing...
MarketBeat·13d ago
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP XL Venous Vascular Closure System
Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP XL Venous Vascular Closure System Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP XL Venous Vascular Closure System PR Newswire BOSTON, March 30, 2026 VASCADE MVP XL now approved for larger sheaths...
PR Newswire·15d ago
Assenagon Asset Management S.A. Sells 99,083 Shares of Haemonetics Corporation $HAE
Assenagon Asset Management S.A. cut its position in Haemonetics Corporation (NYSE:HAE - Free Report) by 56.4% during the 4th quarter, according to the company in its most recent disclosure with the...
MarketBeat·16d ago
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7%
Haemonetics Corporation (NYSE:HAE - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 1,904,947...
MarketBeat·16d ago
Q2 EPS Estimates for Haemonetics Boosted by Zacks Research
Haemonetics Corporation (NYSE:HAE - Free Report) - Zacks Research boosted their Q2 2028 earnings per share estimates for Haemonetics in a report released on Tuesday, March 24th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $1.47 for...
MarketBeat·18d ago
Q3 EPS Estimates for Haemonetics Increased by Zacks Research
Haemonetics Corporation (NYSE:HAE - Free Report) - Equities research analysts at Zacks Research upped their Q3 2027 earnings per share estimates for shares of Haemonetics in a research report issued on Tuesday, March 24th. Zacks Research analyst Team now anticipates that the medical instruments supp...
MarketBeat·19d ago
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
Key PointsInvenomic sold 498,317 shares of Haemonetics Corporation in the fourth quarter...
Nasdaq News: Markets·25d ago
<
1
2
...
>